Latest Lynx1 Capital Management LP Stock Portfolio
Lynx1 Capital Management LP Performance:
2025 Q4: 23.49%YTD: 63.54%2024: 0.34%
Performance for 2025 Q4 is 23.49%, and YTD is 63.54%, and 2024 is 0.34%.
About Lynx1 Capital Management LP and 13F Hedge Fund Stock Holdings
Lynx1 Capital Management LP is a hedge fund based in San Juan, PR. On 2026-02-17, the fund reported it's updated stock portfolio. In the 13F Holdings report, Lynx1 Capital Management LP reported an equity portfolio of $494 Millions as of 31 Dec, 2025.
The top stock holdings of Lynx1 Capital Management LP are STOK, GHRS, CGEM. The fund has invested 34.7% of it's portfolio in STOKE THERAPEUTICS INC and 26.8% of portfolio in GH RESEARCH PLC.
The fund managers got completely rid off MERUS N V (MRUS), PROTAGONIST THERAPEUTICS INC (PTGX) and ADC THERAPEUTICS SA (ADCT) stocks. They significantly reduced their stock positions in PRECISION BIOSCIENCES INC (DTIL). Lynx1 Capital Management LP opened new stock positions in XENCOR INC (XNCR), IMMATICS N.V (IMTX) and KORRO BIO INC. The fund showed a lot of confidence in some stocks as they added substantially to DENALI THERAPEUTICS INC (DNLI), CULLINAN THERAPEUTICS INC (CGEM) and GH RESEARCH PLC (GHRS).
The top stock holdings of Lynx1 Capital Management LP are STOK, GHRS, CGEM. The fund has invested 34.7% of it's portfolio in STOKE THERAPEUTICS INC and 26.8% of portfolio in GH RESEARCH PLC.
The fund managers got completely rid off MERUS N V (MRUS), PROTAGONIST THERAPEUTICS INC (PTGX) and ADC THERAPEUTICS SA (ADCT) stocks. They significantly reduced their stock positions in PRECISION BIOSCIENCES INC (DTIL). Lynx1 Capital Management LP opened new stock positions in XENCOR INC (XNCR), IMMATICS N.V (IMTX) and KORRO BIO INC. The fund showed a lot of confidence in some stocks as they added substantially to DENALI THERAPEUTICS INC (DNLI), CULLINAN THERAPEUTICS INC (CGEM) and GH RESEARCH PLC (GHRS).
Lynx1 Capital Management LP Annual Return Estimates Vs S&P 500
Our best estimate is that Lynx1 Capital Management LP made a return of 23.49% in the last quarter. In trailing 12 months, it's portfolio return was 63.54%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| xencor inc | 10,802,100 |
| immatics n.v | 9,680,480 |
| korro bio inc | 5,430,100 |
| neuphoria therapeutics inc | 3,395,880 |
| agios pharmaceuticals inc | 2,167,360 |
| cg oncology inc | 1,311,660 |
| arrowhead pharmaceuticals in | 799,535 |
| entrada therapeutics inc | 531,363 |
New stocks bought by Lynx1 Capital Management LP
Additions
| Ticker | % Inc. |
|---|---|
| denali therapeutics inc | 564 |
| cullinan therapeutics inc | 55.45 |
| gh research plc | 20.99 |
| design therapeutics inc | 5.4 |
| tscan therapeutics inc | 2.06 |
Additions to existing portfolio by Lynx1 Capital Management LP
Reductions
| Ticker | % Reduced |
|---|---|
| precision biosciences inc | -4.67 |
Lynx1 Capital Management LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| merus n v | -144,439,000 |
| adc therapeutics sa | -5,303,390 |
| ibio inc | -874,072 |
| protagonist therapeutics inc | -46,501,900 |
| allogene therapeutics inc | -677,188 |
Lynx1 Capital Management LP got rid off the above stocks
Sector Distribution
Lynx1 Capital Management LP has about 69.2% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 69.2 |
| Others | 30.8 |
Market Cap. Distribution
Lynx1 Capital Management LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
- SMALL-CAP
- UNALLOCATED
- MID-CAP
- MICRO-CAP
- NANO-CAP
| Category | % |
|---|---|
| SMALL-CAP | 56.4 |
| UNALLOCATED | 30.8 |
| MID-CAP | 6 |
| MICRO-CAP | 5.2 |
| NANO-CAP | 1.6 |
Stocks belong to which Index?
About 62.4% of the stocks held by Lynx1 Capital Management LP either belong to S&P 500 or RUSSELL 2000 index.
- RUSSELL 2000
- Others
| Index | % |
|---|---|
| RUSSELL 2000 | 62.4 |
| Others | 37.6 |
Lynx1 Capital Management LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Lynx1 Capital Management LP
Lynx1 Capital Management LP has 22 stocks in it's portfolio. About 97.2% of the portfolio is in top 10 stocks. TCRX proved to be the most loss making stock for the portfolio. STOK was the most profitable stock for Lynx1 Capital Management LP last quarter.
Last Reported on: 17 Feb, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ADCT | adc therapeutics sa | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AGIO | agios pharmaceuticals inc | 0.44 | 79,624 | 2,167,360 | new | |||
| ALLO | allogene therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| APLT | applied therapeutics inc | 0.01 | 410,500 | 41,050 | new | |||
| ARWR | arrowhead pharmaceuticals in | 0.16 | 12,043 | 799,535 | new | |||
| CCCC | c4 therapeutics inc | 2.74 | 7,098,130 | 13,557,400 | unchanged | 0.00 | ||
| CGEM | cullinan therapeutics inc | 18.78 | 8,963,500 | 92,772,200 | added | 55.45 | ||
| DNLI | denali therapeutics inc | 5.81 | 1,738,750 | 28,706,800 | added | 564 | ||
| DSGN | design therapeutics inc | 0.13 | 69,516 | 652,060 | added | 5.4 | ||
| DTIL | precision biosciences inc | 0.84 | 993,913 | 4,134,680 | reduced | -4.67 | ||
| GBIO | generation bio co | 0.03 | 25,000 | 142,000 | new | |||
| GHRS | gh research plc | 26.75 | 10,406,600 | 132,164,000 | added | 20.99 | ||
| HOWL | werewolf therapeutics inc | 0.08 | 655,926 | 415,529 | new | |||
| IBIO | ibio inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| IMTX | immatics n.v | 1.96 | 921,950 | 9,680,480 | new | |||
| MRUS | merus n v | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| PASG | passage bio inc | 1.49 | 623,704 | 7,359,710 | unchanged | 0.00 | ||
| PRQR | proqr thrapeutics n v | 0.03 | 68,486 | 138,342 | new | |||
| PTGX | protagonist therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| STOK | stoke therapeutics inc | 34.73 | 5,404,670 | 171,544,000 | unchanged | 0.00 | ||